Diffusion-Weighted MR Imaging of Early Methotrexate-Related Neurotoxicity in Children

References

1. ↵
   Lo Nigro L, Di Cataldo A, Schiliro G. Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols. Med Pediatr Oncol 2000;35:449–455

   CrossRefPubMedWeb of Science
2. ↵
   Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy: a Pediatric Oncology Group study. J Clin Oncol 1998;16:1712–1722

   Abstract
3. ↵
   Shuper A, Stark B, Kornreich L, et al. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol 2000;15:573–580

   Abstract/FREE Full Text
4. ↵
   Chessells JM, Cox TC, Kendall B, et al. Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation. Arch Dis Child 1990;65:416–422

   Abstract/FREE Full Text
5. ↵
   Jaffe N, Takaue Y, Anzai T, Robertson R. Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 1985;56:1356–1360

   CrossRefPubMedWeb of Science
6. ↵
   Gowan GM, Herrington JD, Simonetta AB. Methotrexate-induced toxic leukoencephalopathy. Pharmacotherapy 2002;22:1183–1187

   CrossRefPubMed
7. ↵
   Matsumoto K, Takahashi S, Sato A, et al. Leukoencephalopathy in childhood hematopoietic neoplasm caused by moderate-dose methotrexate and prophylactic cranial radiotherapy: an MR analysis. Int J Radiat Oncol Biol Phys 1995;32:913–918

   CrossRefPubMed
8. Lien HH, Blomlie V, Saeter G, et al. Osteogenic sarcoma: MR signal abnormalities of the brain in asymptomatic patients treated with high-dose methotrexate. Radiology 1991;179:547–550

   PubMedWeb of Science
9. ↵
   Asato R, Akiyama Y, Ito M, et al. Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate. Cancer 1992;70:1997–2004

   CrossRefPubMedWeb of Science
10. ↵
    Keime-Guibert F, Napolitano M, Delattre JY. Neurological complications of radiotherapy and chemotherapy. J Neurol 1998;245:695–708

    CrossRefPubMedWeb of Science
11. ↵
    Lamy C, Oppenheim C, Meder JF, Mas JL. Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging 2004;14:89–96

    CrossRefPubMedWeb of Science
12. ↵
    Kinoshita T, Moritani T, Shrier DA, et al. Diffusion-weighted MR imaging of posterior reversible leukoencephalopathy syndrome: a pictorial essay. Clin Imaging 2003;27:307–315

    CrossRefPubMedWeb of Science
13. ↵
    Nelson RW, Frank JT. Intrathecal methotrexate-induced neurotoxicities. Am J Hosp Pharm 1981;38:65–68

    Abstract
14. ↵
    Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994;20:191–214

    CrossRefPubMedWeb of Science
15. ↵
    Bernini JC, Fort DW, Griener JC, et al. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995;345:544–547

    CrossRefPubMedWeb of Science
16. ↵
    Drachtman RA, Cole PD, Golden CB, et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002;19:319–327

    CrossRefPubMedWeb of Science
17. ↵
    Romero JM, Schaefer PW, Grant PE, et al. Diffusion MR imaging of acute ischemic stroke. Neuroimaging Clin N Am 2002;12:35–53

    CrossRefPubMed
18. ↵
    Peyriere H, Poiree M, Cociglio M, et al. Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline. Med Pediatr Oncol 2001;36:662–664

    CrossRefPubMed